Literature DB >> 31299857

PACAP27 induces migraine-like attacks in migraine patients.

Hashmat Ghanizada1, Mohammad Al-Mahdi Al-Karagholi1, Nanna Arngrim1, Jes Olesen1, Messoud Ashina1.   

Abstract

INTRODUCTION: Pituitary adenylate cyclase-activating polypeptide (PACAP) is found in two functional isoforms, namely PACAP38 and PACAP27. The migraine-inducing properties of PACAP38 are well studied. However, it is not known whether the lesser-known and under-studied protein isoform, PACAP27, can also induce migraine attacks. Here, we studied the effect of human PACAP27 infusion on induction of migraine in a provocation model.
METHODS: In a crossover study, 20 migraine without aura patients were randomly assigned to receive human PACAP27 (10 picomol/kg/min) or saline (placebo) infusion over 20 min. We recorded the migraine and associated symptoms.
RESULTS: All patients completed the study. PACAP27 provoked migraine-like attacks in 11 patients (55%) and two developed attacks after placebo (10%) (p = 0.022). The headache intensity and duration after PACAP27 was significantly greater compared to placebo (p = 0.003).
CONCLUSION: PACAP27 triggers migraine attacks without aura. These novel data strengthen the role of PACAP and its receptors in migraine pathogenesis.

Entities:  

Keywords:  Pituitary adenylate cyclase-activating polypeptide; cyclic adenosine monophosphate; flushing; headache; migraine; vasoactive intestinal polypeptide

Mesh:

Substances:

Year:  2019        PMID: 31299857     DOI: 10.1177/0333102419864507

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

1.  New discoveries in migraine mechanisms and therapeutic targets.

Authors:  Greg Dussor
Journal:  Curr Opin Physiol       Date:  2019-10-18

Review 2.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

3.  Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Christopher S Walker; Nanna Arngrim; Tayla Rees; Jakeb Petersen; Andrew Siow; Mette Mørch-Rasmussen; Sheryl Tan; Simon J O'Carroll; Paul Harris; Lene Theil Skovgaard; Niklas Rye Jørgensen; Margaret Brimble; Jayme S Waite; Brandon J Rea; Levi P Sowers; Andrew F Russo; Debbie L Hay; Messoud Ashina
Journal:  Ann Neurol       Date:  2021-04-08       Impact factor: 11.274

Review 4.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

5.  A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.

Authors:  Messoud Ashina; David Doležil; Jo H Bonner; Lifen Zhou; Jan Klatt; Hernan Picard; Daniel D Mikol
Journal:  Cephalalgia       Date:  2020-11-24       Impact factor: 6.292

6.  Ictal and interictal brain activation in episodic migraine: Neural basis for extent of allodynia.

Authors:  Nasim Maleki; Edina Szabo; Lino Becerra; Eric Moulton; Steven J Scrivani; Rami Burstein; David Borsook
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

Review 7.  Brain barriers and their potential role in migraine pathophysiology.

Authors:  Astrid Wiggers; Håkan Ashina; Nouchine Hadjikhani; Abhay Sagare; Berislav V Zlokovic; Martin Lauritzen; Messoud Ashina
Journal:  J Headache Pain       Date:  2022-01-26       Impact factor: 7.277

8.  Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Nanna Arngrim; Mette Mørch-Rasmussen; Matias Metcalf-Clausen; Henrik Bo Wiberg Larsson; Faisal Mohammad Amin; Messoud Ashina
Journal:  J Headache Pain       Date:  2020-02-24       Impact factor: 7.277

9.  The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers.

Authors:  Hande Coskun; Fatima Azzahra Elbahi; Mohammad Al-Mahdi Al-Karagholi; Hashmat Ghanizada; Majid Sheykhzade; Messoud Ashina
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

10.  Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial.

Authors:  Lanfranco Pellesi; Mohammad Al-Mahdi Al-Karagholi; Roberto De Icco; Hande Coskun; Fatima Azzahra Elbahi; Cristina Lopez-Lopez; Josefin Snellman; Jens Hannibal; Faisal Mohammad Amin; Messoud Ashina
Journal:  JAMA Netw Open       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.